Y. Ho Shin

Nov 1, 2024 | sciencedirect.com | Nikolaos Lazaridis |Edward J Despott |Debra J. Palmer |Y. Ho Shin

Section snippetsReal-world data studiesIn children 6 to 11 years of age, the efficacy and safety of omalizumab as add-on therapy supported by randomized controlled trial (RCT) evidence have been confirmed in real-world studies (RWS) (Table I).